Streptococcus pneumoniae Infection Models

Streptococcus pneumoniae (S. pneumoniae), the pneumococcus, is a Gram-positive coccus and one of the most significant bacterial pathogens of humans. It colonizes the nasopharynx asymptomatically, especially in children, and from there causes a wide range of disease. It is a leading cause of community-acquired pneumonia and bacterial meningitis, a common cause of bloodstream infection, and the classic cause of acute otitis media and sinusitis. The very young, the elderly, and people with weakened immunity or chronic lung disease are at highest risk.

Its defining virulence factor is a polysaccharide capsule, which shields it from phagocytosis and defines the more than ninety serotypes on which the pneumococcal vaccines are built. That vaccine has reshaped the disease, driving down infections caused by covered serotypes, but non-vaccine serotypes and drug resistance continue to sustain the burden.

The CDC classifies drug-resistant S. pneumoniae as a serious threat, and the WHO lists macrolide-resistant S. pneumoniae in the medium-priority tier of its 2024 Bacterial Priority Pathogens List. TransPharm Preclinical Solutions evaluates candidates against S. pneumoniae in vivo across four validated infection models and produces the quantitative burden and survival data a development program needs.

The scientific problem in an S. pneumoniae study is matching both the model and the serotype to the question. The pneumococcus causes disease across several compartments (lung, bloodstream, and middle ear) and TransPharm Preclinical Solutions’s models span that range, so the site can be chosen to fit the indication. Serotype is the second variable, and it matters more here than for most pathogens: capsular type shapes virulence, tissue tropism, and vaccine relevance, so a well-characterized laboratory serotype such as D39 (serotype 2) and a clinical isolate of a vaccine-relevant or resistant serotype answer different questions. Resistance is the third: because penicillin resistance in the pneumococcus arises from remodeled drug targets rather than a single acquired enzyme, a penicillin- or macrolide-resistant isolate is often the necessary challenge for a candidate positioned against resistant disease.

TransPharm Preclinical Solutions maintains an on-site library of hundreds of validated pathogens and can source or validate characterized S. pneumoniae isolates, including defined serotypes and resistant phenotypes, to a program’s specifications.

Every study parameter is configurable to the scientific question: challenge strain and serotype, host species and strain, route of administration, comparator agents, and dosing schedule. The core readouts are quantitative bacterial burden (CFU) in target tissues, organs, and blood, with survival and mortality tracking where applicable.

The following are available as add-ons to any study:

• Pharmacokinetic profiling and PK/PD analysis
• Blood chemistry
• Additional tissue harvests
• Histopathology

Pneumococcal pneumonia is the flagship S. pneumoniae disease, and the pulmonary model is the appropriate choice when the development question is reduction of lung burden, survival after airway challenge, or delivery of an inhaled or systemically dosed agent to infected lungs. Animals are challenged by intranasal or intratracheal instillation. Test article may be delivered by nebulization, oral gavage, intranasal or intratracheal instillation, or by intravenous, intraperitoneal, intramuscular, or subcutaneous injection. Endpoints include survival and CFU burden in lung and other harvested tissues. Validated in mice and rats. Validated S. pneumoniae isolates: ATCC 10813, D39 (serotype 2), and ATCC 700674.

Uncontrolled pneumococcal infection can seed the bloodstream, and invasive pneumococcal disease carries high mortality. The bacteremia model screens systemic activity and ranks candidates on survival and on bacterial burden in blood and organs. Animals are challenged by intravenous injection in the lateral tail vein. Test article may be administered by oral gavage or by subcutaneous, intravenous, or intraperitoneal injection. Endpoints include survival (mortality tracking) and CFU burden in harvested organs and/or blood. Validated in mice, with rats available on request. Validated S. pneumoniae isolate: ATCC 700674, a penicillin-intermediate reference strain.

Acute otitis media is one of the most common bacterial infections of childhood, and S. pneumoniae is a principal cause, making this model a distinctive capability for programs targeting ear infection. TransPharm Preclinical Solutions’s otitis media model is established in rats: a histamine solution is injected into both tympanic membranes to impair mucociliary clearance through the eustachian tube, and animals then receive a single challenge by intranasal instillation. Test article may be administered by ear drops, oral gavage, or subcutaneous, intravenous, intramuscular, or intraperitoneal injection. The endpoint is CFU burden in harvested tissues and/or blood. Validated S. pneumoniae isolate: BEISPEC6B.

The soft tissue model establishes a localized infection in the muscle by intramuscular injection into one or both quadriceps, giving a quantifiable burden well suited to PK/PD and dose-ranging work. Test article may be administered by oral gavage or by subcutaneous, intravenous, or intraperitoneal injection. Endpoints include CFU burden at the infected site and in harvested organs and/or blood, with mortality tracking. Validated in mice.

In vitro susceptibility testing complements the in vivo models. S. pneumoniae MIC is determined by broth microdilution per CLSI, and can be paired with MBC, time-kill, and checkerboard analysis to characterize a candidate and its combinations against susceptible and resistant isolates.

The pneumococcus is unusual among priority pathogens in that a vaccine, not just an antibiotic, shapes its resistance – but resistance remains a serious and growing problem. It differs mechanistically from most Gram-positive resistance: S. pneumoniae does not produce a β-lactamase but instead acquires mosaic pbp genes by transformation, remodeling its penicillin-binding proteins so that penicillins and other β-lactams bind less well.

Macrolide resistance, now found in roughly forty percent of U.S. isolates, is driven by ribosomal methylation (ermB) and efflux (mefA/E); fluoroquinolone resistance arises from gyrA and parC mutations, and tetracycline resistance from tetM. Pneumococcal conjugate vaccines sharply reduced disease from the resistant serotypes they cover, but serotype replacement by non-vaccine types – some of them multidrug-resistant, such as serotype 19A before its inclusion in later vaccines – continues to shift the landscape. Because resistance is serotype-linked and target-mediated, the serotype and susceptibility profile of the challenge strain, not the species label, determine what an efficacy study can claim.